Amikacin Sulfate Injection

Amikacin sulfate is an aminoglycoside antibiotic. This product has a good effect on most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, Citrobacter, Serratia, etc. It also has a good effect on Pseudomonas aeruginosa and some other Pseudomonas, Acinetobacter, Alcaligenes, etc. It also has a good antibacterial effect on meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some mycobacteria. Its antibacterial activity is slightly lower than that of gentamicin. The most prominent advantage of this product is that it is stable to the aminoglycoside inactivating enzymes produced by many intestinal Gram-negative bacteria and will not be inactivated by such enzymes and lose its antibacterial activity. Among the 12 inactivating enzymes currently isolated, This product can only be inactivated by AAC (6). In addition, AAD (4) and APH (3)-III may occasionally cause bacteria to have moderate resistance to this product. Among clinically isolated Enterobacteriaceae, about 60% to 70% of those resistant to aminoglycosides such as gentamicin, tobramycin and netilmicin are still sensitive to this product. In recent years, the number of amikacin-resistant strains among Gram-negative bacteria has also increased. Among Gram-positive cocci, this product has a good antibacterial effect on methicillin-sensitive strains of Staphylococcus, while Streptococcus pneumoniae, various groups of Streptococci and Enterococcus are mostly resistant to it. This product is ineffective against anaerobic bacteria. Its mechanism of action is to act on the 30S subunit of the bacterial ribosome and inhibit bacterial protein synthesis. Amikacin can often achieve a synergistic antibacterial effect when used in combination with semi-synthetic penicillins or cephalosporins.

The main ingredient of this product is: Amikacin sulfate.

This product is suitable for serious infections caused by sensitive Gram-negative bacteria such as Pseudomonas aeruginosa and other Pseudomonas, Escherichia coli, Proteus, Klebsiella, Enterobacter, Serratia, Acinetobacter, and Staphylococcus (methicillin-sensitive strains), such as bacteremia or sepsis, bacterial endocarditis, lower respiratory tract infection, bone and joint infection, biliary tract infection, abdominal infection, complicated urinary tract infection, skin and soft tissue infection, etc. Since this product is stable to most aminoglycoside inactivating enzymes, it is particularly suitable for the treatment of serious infections caused by Gram-negative bacteria resistant to kanamycin, gentamicin or tobramycin.

1 Adults, intramuscular injection or intravenous drip. For simple urinary tract infection resistant to commonly used antibiotics, 0.2g every 12 hours; for other systemic infections, 7.5mg/kg every 12 hours, or 15mg/kg every 24 hours. No more than 1.5g per day for adults, and the course of treatment shall not exceed 10 days. 2 Children, intramuscular injection or intravenous drip. The first dose is 10mg/kg according to body weight, followed by 7.5mg/kg every 12 hours, or 15mg/kg every 24 hours. 3 Patients with impaired renal function: For patients with creatinine clearance of 50-90ml/min, 60-90% of the normal dose (7.5mg/kg) is given every 12 hours; for patients with creatinine clearance of 10-50ml/min, 20-30% of 7.5mg/kg is used every 24-48 hours.

1 Patients may experience hearing loss, tinnitus, or a feeling of fullness in the ears; a few patients may also experience dizziness, unsteady gait, and other symptoms. Hearing loss symptoms generally stop getting worse after drug discontinuation, but some may continue to develop into deafness after drug discontinuation. 2 This product has a certain degree of nephrotoxicity, and patients may experience hematuria, decreased urination frequency or urine volume, increased blood urea nitrogen, and blood creatinine. Most of them are reversible and will be alleviated after drug discontinuation, but there are also individual reports of renal failure. 3 Neuromuscular blocking effects such as weakness, drowsiness, and dyspnea are rare. 4 Other adverse reactions include headache, numbness, needle infection, tremor, convulsion, joint pain, drug fever, eosinophilia, abnormal liver function, blurred vision, etc.

It is contraindicated in patients who are allergic to amikacin or other aminoglycosides.

1. This product combined with other aminoglycosides or applied topically or systemically successively may increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. This product combined with neuromuscular blocking drugs may aggravate neuromuscular blocking effects, leading to symptoms such as muscle weakness and respiratory depression. This product combined with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), etc., or applied topically or systemically successively may increase ototoxicity and nephrotoxicity. 3. This product combined with cephalothin or cefazolin topically or systemically may increase nephrotoxicity. This product should not be used with injections such as amphotericin B, cephalothin, sulfadiazine and tetracycline, and should not be dripped in the same bottle. 4. This product combined with polymyxin injections or applied topically or systemically successively may increase nephrotoxicity and neuromuscular blocking effects. 5. Other nephrotoxic and ototoxic drugs should not be used together with this product or applied successively to avoid aggravating nephrotoxicity or ototoxicity.

Keep tightly closed in a cool, dark place.

2ml:0.2g (200,000 units)

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

• Founded in:

  1962-12-27

• Address:

  No. 48, North Industrial Avenue, Haizhu District, Guangzhou

• Tax NO.:

  9144010119046020XE

• Registered Funds:

  46.091897 yuan

• Website:

  Log in to view

• Email:

  Log in to view